[{"orgOrder":0,"company":"Lucy Scientific Discovery","sponsor":"Wesana Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lucy Scientific Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Lucy Scientific Discovery \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Lucy Scientific Discovery \/ Lucy Scientific Discovery"}]

Find Clinical Drug Pipeline Developments & Deals by Lucy Scientific Discovery

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Through the acquisition, Lucy will add Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental healt...

                          Brand Name : SANA-013

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 21, 2023

                          Lead Product(s) : Psilocybine,Cannabidiol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Recipient : Wesana Health

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank